The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.
Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy
Open accessAbstract
Background/Objectives: The safe completion of a non-invasive procedure is crucial to the success of an endovascular approach. Chitosan, a natural polysaccharide derived from chitin, is an ideal material for the study and application of medical devices in post-operative wound management. Methods: The present work is based on a retrospective study conducted on a sample of patients treated with Axiostat (a sterile, single-use, non-absorbable dressing), composed of 100% chitosan and designed to instantly stop bleeding through a mucus adhesion mechanism for the treatment of conditions such as Leriche’s syndrome. The objective was to evaluate the efficacy and safety of the hemostatic Axiostat dressing in patients undergoing anticoagulant and/or antiplatelet therapy in whom endovascular procedures using the axillary artery as an access site are performed to treat Leriche syndrome. Results: The obtained results showed that Axiostat is safe and effective in promoting hemostasis at the axillary vascular access site even when prolonged hemostasis was required in patients on antiplatelet and anticoagulant therapy. The mean time to hemostasis was 5.75 min in all types of patients considered.
Overview
CoChat Summary
TL;DR
In a single-center retrospective study of 60 patients with Leriche syndrome undergoing endovascular procedures via left axillary access, adjunctive Axiostat chitosan dressing with manual compression achieved a mean time to hemostasis of 5.75 min despite anticoagulant/antiplatelet therapy. The authors conclude Axiostat is safe and effective, while calling for multicenter randomized trials.
Key findings
- Among 60 patients (mean age 67.4 years), primary success was 100% in single- and dual-antiplatelet therapy and 95–98% in anticoagulant and/or combined anticoagulant therapy; mean time to hemostasis was 5.75 min, with median approximately 5 min.
- At the end of the 10 min observation period, hemostatic success was 99.5% (later stated as 100% in Table 5); healing at 7- and 30-day follow-up occurred in 99.9% of cases.
- Access-site complication rate was 1.8%, including one hematoma in patients on anticoagulant therapy and two in patients on anticoagulant and/or combination antiplatelet therapy; five pseudoaneurysms occurred in dual antiplatelet therapy and two in anticoagulant therapy; 1.2% required surgical intervention, with no dissection or arteriovenous fistula.
- Mean INR before and after treatment was 1.3 (±0.2); PCA using the first two principal components captured approximately 73% of total variance, with higher BMI, diabetes, and hyperlipidemia associated with prolonged hemostasis times.
Methods
- Monocentric retrospective analysis at Annunziata Hospital, Cosenza, Italy, from September 2022 to February 2024, including 60 consecutive patients who underwent endovascular treatment for Leriche syndrome with left axillary artery access and Axiostat-assisted manual compression; inclusion and exclusion criteria were specified.
- Procedure included local lidocaine anesthesia, CT and ultrasound assessment, percutaneous access via Seldinger technique, heparin 5000 I.U., kissing stent placement (Begraft 8 × 57 mm), then three-finger manual compression with Axiostat for 10 min for 4–8 Fr sheaths, followed by a secondary adhesive compression dressing for 12 h and ultrasound follow-up.
- Statistical analysis used one-way ANOVA and Brown–Forsythe tests with p < 0.05 and p < 0.001 thresholds in MATLAB R2023a; PCA was performed with normalization and centering using The Unscrambler X 10.4.
Limitations
- Paper-stated: retrospective single-center observational design, lack of randomization, and absence of a control group; the authors note the need to extend the study to other vascular surgery departments and larger populations, to include CT at last follow-up, to use standardized cross-checked data collection forms, and to conduct multicenter randomized clinical trials.
- Evident from the text: the sample is small (n = 60) and single-center, limiting generalizability; some reported outcome numbers are internally inconsistent (e.g., a 1.8% complication rate alongside one and two hematoma cases, and 99.5% versus 100% 10-min hemostatic success), which may affect reliability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
0 Valid · 0 Not valid · 15 Not checked · 43 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Healing with follow-up of the axillary access site at 7 and 30 days occurred in 99.9% of cases (Figure 2).”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.3. Outcomes E Follow-Up
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Controlling for differences in the level of pre-treatment bleeding, the median time for hemostasis was approximately 5 min after its use combined with manual compression by the surgeon (Figure 3).”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.4. Hemostasis Evaluation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients with metabolic disorders tended to exhibit prolonged bleeding times.”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 3. Discussion
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean INR value, measured before and after treatment, was 1.3 (±0.2), confirming the fact that in this type of procedure, it is not necessary to suspend the patients’ anticoagulant regimens as the immediate hemostatic action of Axiostat reduces local hemorrhagic complications, ensuring that therapeutic INR levels are maintained.”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.2. Procedure Data
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“among the observed complications, pseudoaneurysms were more common in patients undergoing multiple punctures.”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 3. Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 58 claims and to verify the 24 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 21
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.4. Hemostasis Evaluation
“At the end of the 10 min observation period, the hemostatic success of lesions treated with Axiostat was 99.5%.”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.4. Hemostasis Evaluation
“At the end of the 10 min observation period, the hemostatic success of lesions treated with Axiostat was 100% (Table 5).”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 3. Discussion
“The results obtained from our studies show us that the primary, secondary and clinical technical success rate was 99.9%”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.3. Outcomes E Follow-Up
“The primary success rate resulting from the application of Axiostat was 100% in patients undergoing endovascular treatment undergoing single-antiplatelet and double-antiplatelet therapy; whereas it was 95–98% in patients undergoing anticoagulant and/or combined anticoagulant therapy”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.3. Outcomes E Follow-Up
“No patients experienced any complications in either procedure.”
§ Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy > 2. Results > 2.3. Outcomes E Follow-Up
“There were also five cases of pseudoaneurysm formation in patients on dual antiplatelet therapy and two cases in those on anticoagulant therapy. In addition, only 1.2% required surgical intervention with closure of the axillary artery due to excessive bleeding and/or infection of the access site (Table 4).”
Citations
Cites
Moeini, A., Pedram, P., Makvandi, P., Malinconico, M., & Gomez d'Ayala, G. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.115839 · Cited by 691
Chitosan-Based Functional Materials for Skin Wound Repair: Mechanisms and Applications
Feng, P., Luo, Y., Ke, C., Qiu, H., Wang, W., Zhu, Y., Hou, R., Xu, L., & Wu, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.650598 · Cited by 491
Mawazi, S. M., Kumar, M., Ahmad, N., Ge, Y., & Mahmood, S. (2024) · Polymers · doi:10.3390/polym16101351 · Cited by 262
Chemometric Methods for Spectroscopy-Based Pharmaceutical Analysis
Biancolillo, A., & Marini, F. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00576 · Cited by 250
Chitosan-Based Biomaterials for Hemostatic Applications: A Review of Recent Advances
Gheorghiță, D., Moldovan, H., Robu, A., Biță, A.-I., Grosu, E., Antoniac, A., Corneschi, I., Antoniac, I., Bodog, A., & Bacila, C. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310540 · Cited by 184
Hemostatic materials in wound care
Yu, P., & Zhong, W. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab019 · Cited by 166
Emerging materials for hemostasis
Li, X.-F., Lu, P., Jia, H.-R., Li, G., Zhu, B., Wang, X., & Wu, F.-G. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214823 · Cited by 164
Cao, S., Xu, G., Li, Q., Zhang, S., Yang, Y., & Chen, J. (2022) · Composites Part B: Engineering · doi:10.1016/j.compositesb.2022.109746 · Cited by 140
The Society for Vascular Surgery clinical practice guidelines on popliteal artery aneurysms
Farber, A., Angle, N., Avgerinos, E., Dubois, L., Eslami, M., Geraghty, P., Haurani, M., Jim, J., Ketteler, E., Pulli, R., et al. (2022) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2021.04.040 · Cited by 127
Recent advances in biopolymer-based hemostatic materials
Mecwan, M., Li, J., Falcone, N., Ermis, M., Torres, E., Morales, R., Hassani, A., Haghniaz, R., Mandal, K., Sharma, S., et al. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac063 · Cited by 88
Research works printed but not linked: 2
- Kholmurodov, 2023, Leriche’s Syndrome, Gold. Brain, 1, 104
- Archer, 2023, The seldinger technique: A revolution in medicine, ANZ J. Surg., 93, 184
Cited by
Functional roles and applications of polysaccharides in biomedical and food systems
Atepileva, A., Kudaibergen, G. K., Krivoruchko, T., Zhulikeyeva, A., Amantay, N., Unysheva, G., Akhmetkarimova, Z. S., & Alzhanov, Y. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1774298 · Cited by 11
Biological Macromolecule-Based Dressings for Combat Wounds: From Collagen to Growth Factors—A Review
Kamysz, W., & Kleczkowska, P. (2025) · Medical Sciences · doi:10.3390/medsci13030106 · Cited by 10
Putra, O. N., Musfiroh, I., Gazzali, A. M., Chaidir, C., Paramitasari, D., Pudjianto, K., Kusnadi, K., Fakih, T. M., & Muchtaridi, M. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s616342 · Cited by 1
Hoàng, V., Nguyen, X. V., & Vu, Q. N. (2026) · Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế · doi:10.38103/jcmhch.18.2.18
Yu, Y., Wang, L., Liu, X., Jin, N., Zhang, S., Li, G., & Xu, M. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.116109
Metadata
- Authors
- Perri, P., Curcio, F., De Luca, M., Piro, P., Trombino, S., & Cassano, R.
- Affiliations
- Ospedale Annunziata di Cosenza (IT)
- University of Calabria (IT)
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Arcavacata, 87036 Rende, Italy
- Corresponding author
- Trombino, Sonia
- Cassano, Roberta
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2025-04-16
- Volume
- 18
- Issue
- 4
- Pages
- 584
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC12030152
- OpenAlex
- W4409503510
- Cited by
- 6
- References
- 27
- Citations by year
- 2026: 5 · 2025: 1
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Funders
- Department of Pharmacy and Health and Nutrition Sciences Department of Excellence L. (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
- PON R&I (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
- Development and Industrialization of Innovative Drugs for Personalized Molecular Therapy (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
- Topics
- Health Sciences › Medicine › Hematology › Hemostasis and retained surgical items
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vascular Procedures and Complications
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Central Venous Catheters and Hemodialysis
- Keywords
- chitosan, hemostatic dressings, Leriche syndrome, anticoagulation, antiplatelet therapy, endovascular intervention, axillary artery access, mucus adhesion, wound care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy. https://app.cochat.ai/papers/10.3390/ph18040584
- The paper
- Perri, P., Curcio, F., De Luca, M., Piro, P., Trombino, S., & Cassano, R. (2025). Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy. Pharmaceuticals. https://doi.org/10.3390/ph18040584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.